Hi VRS, yes I have & no we haven’t discussed Dapa trials here in detail here, but if you’d like to post that, I’m sure that you would have an interested group of people to discuss with, including me & most welcome to do so.
As you would know SGLT2 class is not tolerated by all patients with CKD/DKD, but they are certainly achieving some remarkable results. I am also hoping to see some additive benefit for diabetic patients in renal function on top of the 30-40% improvement in eGFR afforded by this class of drugs in diabetes on top of ARB or ACE Inhibitors & also a reduced risk in CVD events. This isn’t unnoticed & a breakthrough class of drugs it now looks like, following Invokana’s approval from the FDA in 2019 resulting in amended recommendations in the USA for screening & treatment.
Oct 2, page-22
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $214.4M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 37.0¢ | $503.5K | 1.322M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 26318 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 170072 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |